<unk>  was approved by the Food and Drug Administration in March 2018, and the European Medicines Agency in September 2018, for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy.<unk>  is administered via subcutaneous injection. It is available as a single-dose prefilled syringe containing 100 mg of<unk>  in 1 ml of solution.
Tildrakizumab
Brolucizumab
Risankizumab
Mogamulizumab
Etaracizumab
Caplacizumab
Ixekizumab
Crizanlizumab